ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Metronidazole

Also written as “metronidazole 1% gel”, “Metronidazole Tablet” and “metronidazole”.

Its studies are mostly in Intraabdominal Infections · Vaginosis, Bacterial · Rosacea · Appendicitis · Skin Manifestations, led by 11 companies.

Drug pageMetronidazole: every studyMany companies study it; this page follows only the 27 they lead. All 226 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 12, 200527 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only80 open or runningphase 4since Sep 12, 2005Sep 12, 2005none ahead
Galderma Groupits history only40 open or runningphase 4since Feb 16, 2007Feb 16, 2007none ahead
S.L.A. Pharma40 open or runningphase 3since Jul 30, 2007Jul 30, 2007none ahead
Curatek Pharmaceuticalsits history only20 open or runningphase 3since Dec 1, 2014Dec 1, 2014none ahead
Par Healthits history only20 open or runningphase 1since Jun 16, 2011Jun 16, 2011none ahead
Teva Pharmaceutical Industriesits history only20 open or runningphase 2since Nov 24, 2009Nov 24, 2009none ahead
Appili Therapeuticsits history only10 open or runningphase 1since Nov 6, 2017Nov 6, 2017none ahead
bioRASIits history only10 open or runningphase 3since Mar 12, 2015Mar 12, 2015none ahead
Dr. Reddy's Laboratoriesits history only10 open or runningphase 2since Mar 19, 2012Mar 19, 2012none ahead
Insud Pharmaits history only10 open or runningphase 4since Mar 4, 2015Mar 4, 2015none ahead

Also a collaborator on its studies: Allergan Sales, AbbVie, Algorithme Pharma and PriCara, Unit of Ortho-McNeil.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of S.L.A. Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 30, 2007First study: phase 3 study in Crohn DiseaseFirst studyNCT00509639 · 74 enrolled · United States, United Kingdom
  2. Oct 16, 2008Phase 1 study in Perianal Crohns'NCT00774969 · 19 enrolled · United Kingdom
  3. Oct 16, 2008Phase 3 study in HaemorrhoidectomyNCT00774722 · 59 enrolled · United Kingdom
  4. Jan 15, 2020Phase 2 study in Pilonidal SinusNCT04273997 · 80 enrolled · Turkey

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“DNA inhibitor; DNA inhibitor”ChEMBL 37, by rule

Studies

All 4 S.L.A. Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04273997Pilonidal Sinus · Turkey2UNKNOWNFeb 1, 202280
NCT00774969Perianal Crohns' · United Kingdom1CompletedApr 200819
NCT00774722Haemorrhoidectomy · United Kingdom3CompletedMar 200859
NCT00509639Crohn Disease · United States, United Kingdom3CompletedFeb 200874

How it is read

Names in the registry

  • “Metronidazole”, 20 entries
  • “metronidazole 1% gel”, 2 entries
  • “Metronidazole Tablet”, 2 entries
  • “metronidazole”, 2 entries
  • “Likmez® (metronidazole) Oral Suspension”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.